Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$14.81 0.0%	$16.44	$12.72 ▼ $34.47	$2.58B	0.66	1.46 million shs	1.13 million shs
KYMR Kymera Therapeutics	$42.36 -0.5%	$44.44	$19.44 ▼ $53.27	$3.03B	2.18	745,152 shs	298,532 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
REPL Replimune Group	$5.27 -0.2%	$8.04	$2.68 ▼ $17.00	$411.14M	0.67	4.08 million shs	1.33 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	-2.88%	-2.56%	-17.25%	+2.85%	-52.45%
KYMR Kymera Therapeutics	-2.41%	+6.77%	-7.82%	+41.29%	-4.44%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
REPL Replimune Group	-0.94%	+0.57%	-56.33%	-37.59%	-48.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	3.0396 of 5 stars	4.4	2.0	0.0	0.0	3.0	1.7	0.0
KYMR Kymera Therapeutics	2.8344 of 5 stars	4.6	1.0	0.0	0.0	1.9	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	4.5438 of 5 stars	4.2	2.0	0.0	4.5	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.83	Moderate Buy	$35.20	137.61% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	39.54% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
REPL Replimune Group	2.33	Hold	$7.67	45.56% Upside

Current Analyst Ratings Breakdown

Latest REPL, MOR, KYMR, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
KYMR Kymera Therapeutics	$44.71M	67.74	N/A	N/A	$13.59 per share	3.12
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	N/A

Latest REPL, MOR, KYMR, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	12.32	12.32
KYMR Kymera Therapeutics	N/A	8.32	8.32
MOR MorphoSys	4.98	1.38	1.38
REPL Replimune Group	0.21	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

REPL, MOR, KYMR, and IMVT Headlines

Recent News About These Companies

REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

1 hour ago | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

4 hours ago | globenewswire.com

Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

August 19 at 4:14 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. ...

August 19 at 9:31 AM | gurufocus.com

Class Action Filed Against Replimune Group, Inc. (REPL) - September 22, 2025 Deadline to Join - Contact Levi & Korsinsky

August 19 at 8:45 AM | prnewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $7.67 Average Target Price from Analysts

August 19 at 2:23 AM | americanbankingnews.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. ...

August 18 at 5:31 PM | gurufocus.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

August 18 at 4:04 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

August 18 at 12:17 PM | globenewswire.com

Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL)

August 18 at 8:45 AM | prnewswire.com

Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Increases By 165.7%

August 18 at 5:32 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. ...

August 18 at 3:30 AM | gurufocus.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 18 at 2:53 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 17 at 10:37 AM | globenewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. ...

August 16, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

August 16, 2025 | prnewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

August 15, 2025 | globenewswire.com

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

August 15, 2025 | prnewswire.com

Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc.

August 15, 2025 | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

August 15, 2025 | prnewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Hold" from Brokerages

August 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REPL, MOR, KYMR, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$14.81 -0.01 (-0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$14.81 0.00 (-0.02%)

As of 04:10 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$42.36 -0.21 (-0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$42.37 +0.01 (+0.02%)

As of 04:10 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/19/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Replimune Group NASDAQ:REPL

$5.27 -0.01 (-0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$5.27 +0.00 (+0.04%)

As of 04:13 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time